Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine.
Cytomegalovirus infections can cause significant morbidity and mortality in immunosuppressed patients, and present antiviral agents have had little efficacy against these infections. We describe the use of an acyclic nucleoside 9-[2-hydroxy-1-(hydroxymethyl) ethoxy methyl]guanine (BW B759U), in the treatment of two patients with cytomegalovirus retinitis. The efficacy of this agent was evident, with healing of retinal lesions and resolution of viremia and viral shedding. BW B759U appears to be similar pharmacokinetically to intravenous acyclovir in terms of half-life, peak serum levels, and renal excretion.
Felsenstein
D
D
D'Amico
D J
DJ
Hirsch
M S
MS
Neumeyer
D A
DA
Cederberg
D M
DM
de Miranda
P
P
Schooley
R T
RT
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000212:Acyclovir / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000378:metabolism / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000382:microbiology; D005654:Fundus Oculi; D015774:Ganciclovir; D006207:Half-Life; D006801:Humans; D008297:Male; D009504:Neutrophils / Q000382:microbiology; D012173:Retinitis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology
D000998:Antiviral Agents; D015774:Ganciclovir; D000212:Acyclovir